The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $865,755 in first-year total cost, median $432,878.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-L (M1)]2
Most frequent institutions
- MEDICAL UNIVERSITY OF SOUTH CAROLINA1
- UNIVERSITY OF COLORADO DENVER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Study of the Safety, Tolerability, and Efficacy of an iPS Cell-based Therapy for Recessive Dystrophic Epidermolysis Bullosa Delivered with a Spray on Skin Device1UG3AR082887-01 | BRUCKNER, ANNA LEEROOP, DENNIS | UNIVERSITY OF COLORADO DENVER, CO | $538,200 | ZHL1 |
| 2023 | Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Chronic Pancreatitis and Its Associated Pain1UG3DK136705-01 | WANG, HONGJUN | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $327,555 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-11-0.1.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.